Laboratory of Molecular Medicine, Department of Clinical Immunology, Sect 7631, Rigshospitalet, Faculty of Health Sciences, University Hospital of Copenhagen, Denmark.
Immunobiology. 2010 Nov;215(11):921-31. doi: 10.1016/j.imbio.2009.10.006. Epub 2009 Nov 24.
The human lectin complement pathway (LCP) involves circulating complexes consisting of mannose-binding lectin (MBL) or ficolins in association with serine proteases named MASP-1, -2 and -3 and a non-enzymatic protein, sMAP. MASP-3 originates from the MASP1 gene through differential splicing and little is known about its biological characteristics. For this reason we expressed recombinant MASP-3 and generated specific monoclonal antibodies to establish biochemical characteristics and to determine the serum levels, the interactions with the LCP recognition molecules and the influence on complement activation of MASP-3.
We expressed rMASP-3 in CHO-DG44 cells and used SDS-PAGE and Western blotting for biochemical characterization. We generated monoclonal antibodies against MASP-3 and developed a quantitative MASP-3 assay to establish the serum levels in 100 Danish blood donors. In addition we assessed the association levels between MASP-3 and Ficolin-2, -3 and MBL using both ELISA and immunoprecipitation techniques. Moreover, we assessed the influence on complement factor C4 deposition.
We found the mean serum MASP-3 concentration to be 6.4mg/l (range: 2-12.9mg/l) and that MASP-3 in serum is primarily found in complex with Ficolin-3. In contrast to this the MASP-3 association with Ficolin-2 and especially with MBL seems to be less evident. rMASP-3 significantly inhibited Ficolin-3 mediated C4 deposition, while the opposite was the case for rMASP-1.
Our results show that MASP-3 is present in relatively high serum concentrations. Moreover, Ficolin-3 is the primary acceptor molecule of MASP-3 among the LCP activator molecules, but MASP-3 appears to down-regulate Ficolin-3 mediated complement activation through the lectin pathway.
人类凝集素补体途径(LCP)涉及循环复合物,由甘露聚糖结合凝集素(MBL)或纤维胶凝蛋白与丝氨酸蛋白酶 MASP-1、-2 和-3 以及一种非酶蛋白 sMAP 组成。MASP-3 来源于 MASP1 基因的差异剪接,其生物学特性知之甚少。因此,我们表达了重组 MASP-3 并生成了特异性单克隆抗体,以建立生化特性,并确定 MASP-3 的血清水平、与 LCP 识别分子的相互作用以及对补体激活的影响。
我们在 CHO-DG44 细胞中表达 rMASP-3,并使用 SDS-PAGE 和 Western blot 进行生化特性分析。我们生成了针对 MASP-3 的单克隆抗体,并开发了一种定量 MASP-3 测定法,以确定 100 名丹麦献血者的血清水平。此外,我们使用 ELISA 和免疫沉淀技术评估了 MASP-3 与纤维胶凝蛋白-2、-3 和 MBL 的关联水平。此外,我们评估了对补体因子 C4 沉积的影响。
我们发现平均血清 MASP-3 浓度为 6.4mg/l(范围:2-12.9mg/l),并且血清中的 MASP-3 主要与纤维胶凝蛋白-3 形成复合物。与此相反,MASP-3 与纤维胶凝蛋白-2 的关联,尤其是与 MBL 的关联似乎不太明显。rMASP-3 显著抑制纤维胶凝蛋白-3 介导的 C4 沉积,而 rMASP-1 则相反。
我们的结果表明,MASP-3 存在于相对较高的血清浓度中。此外,纤维胶凝蛋白-3 是 LCP 激活分子中 MASP-3 的主要受体分子,但 MASP-3 似乎通过凝集素途径下调纤维胶凝蛋白-3 介导的补体激活。